Switch to:
More From Other Websites
How Focusing On Obscure Diseases Made BioMarin A $15 Billion Company Jul 28 2016
BioMarin Pharmaceutical (BMRN) Jumps: Stock Rises 6.6% Jul 28 2016
FDA Accepts BLA for BioMarin's Cerliponase Alfa for CLN2 Disease, Form of Batten Disease Jul 27 2016
FDA Accepts BLA for BioMarin’s Cerliponase Alfa for CLN2 Disease, Form of Batten Disease Jul 27 2016
A breakthrough for biotech? Jul 27 2016
Biomarin Hemophilia Gene Therapy Advances on Strong Study Results Jul 27 2016
Biomarin developing gene therapy for hemophilia Jul 27 2016
BioMarin Provides Positive Proof-of-Concept Data for BMN 270 Gene Therapy in Hemophilia A in Late... Jul 27 2016
BioMarin Provides Positive Proof-of-Concept Data for BMN 270 Gene Therapy in Hemophilia A in Late... Jul 27 2016
2:30 pm BioMarin Pharm announces interim results of an open-label Phase 1/2 study of BMN 270; 6 of 7... Jul 27 2016
JPMorgan Bullish on Biotech: 3 Top Picks to Buy Now Jul 27 2016
What Do Analysts Recommend for Shire? Jul 26 2016
New Voices in Medical Advocacy Often Are Patients Jul 26 2016
BioMarin to Provide Updated Data for BMN 270 in Hemophilia A in Late Breaking Oral Presentation at... Jul 21 2016
Analysts Gauge Alexion Pharmaceuticals’ Return Potential Jul 21 2016
What Are Roche’s Truest Growth Opportunities? Jul 19 2016
Can The Uptrend Continue for with BioMarin Pharmaceutical (BMRN)? Jul 19 2016
BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Change in Directors or Principal Officers Jul 19 2016


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK